End-of-day quote
Colombo S.E.
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
1.1
LKR
|
0.00%
|
|
0.00%
|
+10.00%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
283
|
169.8
|
169.8
|
311.3
|
283
|
339.6
|
Enterprise Value (EV)
1 |
723
|
709.2
|
770.3
|
695
|
945.2
|
534.1
|
P/E ratio
|
90.7
x
|
-2.81
x
|
-1.63
x
|
4.66
x
|
-7.71
x
|
-3.85
x
|
Yield
|
5%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.3
x
|
0.17
x
|
0.2
x
|
0.41
x
|
0.27
x
|
0.64
x
|
EV / Revenue
|
0.77
x
|
0.72
x
|
0.91
x
|
0.93
x
|
0.89
x
|
1.01
x
|
EV / EBITDA
|
24.9
x
|
-905
x
|
-32.2
x
|
10.3
x
|
8.3
x
|
7.37
x
|
EV / FCF
|
12.9
x
|
-11.6
x
|
-26.9
x
|
3.39
x
|
-6.1
x
|
0.95
x
|
FCF Yield
|
7.74%
|
-8.65%
|
-3.72%
|
29.5%
|
-16.4%
|
105%
|
Price to Book
|
1.44
x
|
1.4
x
|
7.22
x
|
3.69
x
|
7.35
x
|
-5.68
x
|
Nbr of stocks (in thousands)
|
283,000
|
283,000
|
283,000
|
283,000
|
283,000
|
283,000
|
Reference price
2 |
1.000
|
0.6000
|
0.6000
|
1.100
|
1.000
|
1.200
|
Announcement Date
|
7/5/18
|
8/31/19
|
12/4/20
|
10/3/21
|
8/31/22
|
8/31/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
937.4
|
988.6
|
847.1
|
750.9
|
1,065
|
526.8
|
EBITDA
1 |
29.07
|
-0.784
|
-23.95
|
67.24
|
113.8
|
72.5
|
EBIT
1 |
27.83
|
-2.153
|
-25.3
|
66.56
|
112.8
|
71.2
|
Operating Margin
|
2.97%
|
-0.22%
|
-2.99%
|
8.86%
|
10.6%
|
13.51%
|
Earnings before Tax (EBT)
1 |
1.264
|
-73.45
|
-87.95
|
40.35
|
-46.12
|
-96.09
|
Net income
1 |
3.119
|
-60.51
|
-104
|
66.83
|
-36.69
|
-88.3
|
Net margin
|
0.33%
|
-6.12%
|
-12.27%
|
8.9%
|
-3.45%
|
-16.76%
|
EPS
2 |
0.0110
|
-0.2138
|
-0.3673
|
0.2361
|
-0.1297
|
-0.3120
|
Free Cash Flow
1 |
55.99
|
-61.32
|
-28.63
|
205
|
-155
|
561.1
|
FCF margin
|
5.97%
|
-6.2%
|
-3.38%
|
27.3%
|
-14.56%
|
106.5%
|
FCF Conversion (EBITDA)
|
192.6%
|
-
|
-
|
304.91%
|
-
|
773.96%
|
FCF Conversion (Net income)
|
1,795.17%
|
-
|
-
|
306.79%
|
-
|
-
|
Dividend per Share
2 |
0.0500
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/5/18
|
8/31/19
|
12/4/20
|
10/3/21
|
8/31/22
|
8/31/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
440
|
539
|
601
|
384
|
662
|
194
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
15.14
x
|
-688
x
|
-25.07
x
|
5.706
x
|
5.818
x
|
2.683
x
|
Free Cash Flow
1 |
56
|
-61.3
|
-28.6
|
205
|
-155
|
561
|
ROE (net income / shareholders' equity)
|
1.57%
|
-38.1%
|
-144%
|
124%
|
-59.7%
|
832%
|
ROA (Net income/ Total Assets)
|
2.53%
|
-0.2%
|
-2.33%
|
7.08%
|
10.7%
|
7.06%
|
Assets
1 |
123.2
|
30,639
|
4,470
|
943.9
|
-342.1
|
-1,251
|
Book Value Per Share
2 |
0.7000
|
0.4300
|
0.0800
|
0.3000
|
0.1400
|
-0.2100
|
Cash Flow per Share
2 |
0.0100
|
0.0300
|
0.0300
|
0.0300
|
0.0900
|
0.0700
|
Capex
1 |
0.31
|
0.82
|
0.44
|
1.54
|
3.73
|
0.14
|
Capex / Sales
|
0.03%
|
0.08%
|
0.05%
|
0.21%
|
0.35%
|
0.03%
|
Announcement Date
|
7/5/18
|
8/31/19
|
12/4/20
|
10/3/21
|
8/31/22
|
8/31/23
|
|
1st Jan change
|
Capi.
|
---|
| +10.00% | 1.05M | | -32.21% | 15.27B | | -31.97% | 10.84B | | -30.42% | 6.06B | | +8.14% | 6.04B | | -11.41% | 5.86B | | -0.88% | 4.71B | | +52.19% | 4.29B | | -12.31% | 3.61B | | -14.86% | 3.33B |
Other Drug Retailers
|